Generic Name:
ustekinumab
Project Status:
Complete
Therapeutic Area:
Ulcerative colitis
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Stelara/Stelara I.V
Project Line:
Reimbursement Review
Project Number:
SR0627-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
Submission Type:
Initial
Fee Schedule:
Schedule B
Indications:
Ulcerative colitis
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.